HTG Molecular Diagnostics Inc.
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DL… Read more
HTG Molecular Diagnostics Inc. - Asset Resilience Ratio
HTG Molecular Diagnostics Inc. (HTGMQ) has an Asset Resilience Ratio of 32.82% as of March 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2022)
This chart shows how HTG Molecular Diagnostics Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down HTG Molecular Diagnostics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.57 Million | 32.82% |
| Total Liquid Assets | $3.57 Million | 32.82% |
Asset Resilience Insights
- Very High Liquidity: HTG Molecular Diagnostics Inc. maintains exceptional liquid asset reserves at 32.82% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
HTG Molecular Diagnostics Inc. Industry Peers by Asset Resilience Ratio
Compare HTG Molecular Diagnostics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for HTG Molecular Diagnostics Inc. (2015–2022)
The table below shows the annual Asset Resilience Ratio data for HTG Molecular Diagnostics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.00% | $0.00 | $17.78 Million | -- |
| 2021-12-31 | 40.52% | $12.34 Million | $30.46 Million | +22.63pp |
| 2020-12-31 | 17.89% | $6.30 Million | $35.20 Million | -38.42pp |
| 2019-12-31 | 56.32% | $25.41 Million | $45.12 Million | +4.50pp |
| 2018-12-31 | 51.82% | $22.68 Million | $43.77 Million | +28.49pp |
| 2016-12-31 | 23.33% | $4.30 Million | $18.45 Million | -48.26pp |
| 2015-12-31 | 71.59% | $28.20 Million | $39.39 Million | -- |